Header Logo

Connection

GABRIEL LOPEZ to RNA, Small Interfering

Back to Details
This is a "connection" page, showing publications GABRIEL LOPEZ has written about RNA, Small Interfering.
GABRIEL LOPEZ
Connection Strength
3.113
RNA, Small Interfering
  1. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014 Feb; 66:110-6.
    View in: PubMed
    Score: 0.297
  2. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 2010 Jan; 267(1):44-53.
    View in: PubMed
    Score: 0.225
  3. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008 Dec 15; 14(24):8143-51.
    View in: PubMed
    Score: 0.209
  4. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13.
    View in: PubMed
    Score: 0.183
  5. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005 Aug 01; 65(15):6910-8.
    View in: PubMed
    Score: 0.166
  6. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092.
    View in: PubMed
    Score: 0.078
  7. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014 Dec; 13(12):2876-85.
    View in: PubMed
    Score: 0.078
  8. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7.
    View in: PubMed
    Score: 0.076
  9. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459.
    View in: PubMed
    Score: 0.075
  10. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov; 3(11):1302-15.
    View in: PubMed
    Score: 0.073
  11. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 2013 Apr 01; 19(7):1806-15.
    View in: PubMed
    Score: 0.070
  12. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012 Dec 15; 18(24):6648-57.
    View in: PubMed
    Score: 0.068
  13. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
    View in: PubMed
    Score: 0.063
  14. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85.
    View in: PubMed
    Score: 0.063
  15. Chitosan hydrogel for localized gene silencing. Cancer Biol Ther. 2011 May 01; 11(9):839-45.
    View in: PubMed
    Score: 0.062
  16. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res. 2011 Jun 01; 17(11):3716-26.
    View in: PubMed
    Score: 0.062
  17. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 2011 Apr 15; 17(8):2250-9.
    View in: PubMed
    Score: 0.061
  18. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1713-21.
    View in: PubMed
    Score: 0.061
  19. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99.
    View in: PubMed
    Score: 0.059
  20. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010 Aug 01; 16(15):3910-22.
    View in: PubMed
    Score: 0.058
  21. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May 01; 70(9):3687-96.
    View in: PubMed
    Score: 0.058
  22. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010 May; 9(5):1180-7.
    View in: PubMed
    Score: 0.057
  23. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 01; 16(1):184-94.
    View in: PubMed
    Score: 0.056
  24. Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. J Neurochem. 2009 Nov; 111(4):1000-10.
    View in: PubMed
    Score: 0.055
  25. Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009; 555:29-42.
    View in: PubMed
    Score: 0.052
  26. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008 Nov 01; 68(21):9078-86.
    View in: PubMed
    Score: 0.052
  27. Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Apoptosis. 2008 Jul; 13(7):915-28.
    View in: PubMed
    Score: 0.051
  28. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2476-83.
    View in: PubMed
    Score: 0.050
  29. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008 Jul; 4(5):669-79.
    View in: PubMed
    Score: 0.050
  30. Strategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem. 2008 Mar; 8(3):248-55.
    View in: PubMed
    Score: 0.050
  31. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008 Mar 05; 100(5):359-72.
    View in: PubMed
    Score: 0.049
  32. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008 Jan 16; 100(2):109-20.
    View in: PubMed
    Score: 0.049
  33. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy. 2007 Sep-Oct; 3(5):480-3.
    View in: PubMed
    Score: 0.047
  34. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res. 2007 Mar; 5(3):241-9.
    View in: PubMed
    Score: 0.046
  35. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24.
    View in: PubMed
    Score: 0.044
  36. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 2007 Jan; 5(1):95-108.
    View in: PubMed
    Score: 0.023
  37. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
    View in: PubMed
    Score: 0.019
  38. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.
    View in: PubMed
    Score: 0.018
  39. N-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain. J Biol Chem. 2012 Sep 28; 287(40):33853-64.
    View in: PubMed
    Score: 0.017
  40. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr 28; 330(2):123-9.
    View in: PubMed
    Score: 0.017
  41. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9.
    View in: PubMed
    Score: 0.016
  42. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011; 6(7):e21121.
    View in: PubMed
    Score: 0.016
  43. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
    View in: PubMed
    Score: 0.015
  44. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010 Aug 09; 18(2):109-21.
    View in: PubMed
    Score: 0.015
  45. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88.
    View in: PubMed
    Score: 0.015
  46. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010 Apr; 6(3):322-9.
    View in: PubMed
    Score: 0.014
  47. Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer. 2009 Jul 15; 125(2):264-75.
    View in: PubMed
    Score: 0.014
  48. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
    View in: PubMed
    Score: 0.014
  49. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.
    View in: PubMed
    Score: 0.013
  50. Signaling mechanisms mediating muscarinic enhancement of GABAergic synaptic transmission in the spinal cord. Neuroscience. 2009 Feb 18; 158(4):1577-88.
    View in: PubMed
    Score: 0.013
  51. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 2008 Dec 04; 27(57):7192-200.
    View in: PubMed
    Score: 0.013
  52. The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Res. 2008 Jun 01; 68(11):4321-30.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.